Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Koehler, Bruno Christian ^a   Scherr, Anna Lena ^a   Lorenz, Stephan ^a   Elssner, Christin ^a   Kautz, Nicole ^a   Welte, Stefan ^a   Jaeger, Dirk ^a   Urbanik, Toni ^a   Schulze Bergkamen, Henning ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CYCLIN D1; OBATOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P21; PROTEIN P27; UVOMORULIN; ABT-737; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; CADHERIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; NITROPHENOL; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CULTURE; CELL CYCLE PROGRESSION; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY ASSAY; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LOW DRUG DOSE; PROTEIN EXPRESSION; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL MOTION; COLORECTAL TUMOR; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CADHERINS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HUMANS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SULFONAMIDES;

EID: 84906994522     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106571     Document Type: Article

References (47)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, et al. (2006) Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 44: 151-157.
3. Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, et al. (2008) Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol 14: 3829-3840.
4. Zhang YL, Pang LQ, Wu Y, Wang XY, Wang CQ, et al. (2008) Significance of Bcl-xL in human colon carcinoma. World J Gastroenterol 14: 3069-3073.
5. Bodur C, Basaga H (2012) Bcl-2 inhibitors: emerging drugs in cancer therapy. Curr Med Chem 19: 1804-1820.
6. Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, et al. (2013) Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood 121: 2689-2703.
7. Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, et al. (2013) Beyond cell death - antiapoptotic bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. PLoS One 8: e76446.
8. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR (2008) Cadherin switching. J Cell Sci 121: 727-735.
9. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2007) A switch from Ecadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 13: 7003-7011.
10. Martinez-Paniagua MA, Baritaki S, Huerta-Yepez S, Ortiz-Navarrete VF, Gonzalez-Bonilla C, et al. (2011) Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle 10: 2792-2805.
11. Even-Ram S, Yamada KM (2005) Cell migration in 3D matrix. Curr Opin Cell Biol 17: 524-532.
12. Kim JK, Diehl JA (2009) Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 220: 292-296.
13. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512.
14. Jin-Song Y, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S, et al. (2011) Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem 113: 810-814.
15. Backus HH, van Riel JM, van Groeningen CJ, Vos W, Dukers DF, et al. (2001) Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 12: 779-785.
16. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH (2011) Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 16: 59-70.
17. Labi V, Grespi F, Baumgartner F, Villunger A (2008) Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ 15: 977-987.
18. Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, et al. (2010) A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 66: 1079-1085.
19. Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, et al. (2010) Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 16: 4038-4045.
20. Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, et al. (2011) Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 118: 1663-1674.
21. Wroblewski D, Jiang CC, Croft A, Farrelly ML, Zhang XD, et al. (2013) OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. PLoS One 8: e84073.
22. Jain HV, Richardson A, Meyer-Hermann M, Byrne HM (2014) Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas. PLoS One 9: e81582.
23. Huang S, Sinicrope FA (2010) Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy 6: 256-269.
24. Raats DA, de Bruijn MT, Steller EJ, Emmink BL, Borel-Rinkes IH, et al. (2011) Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737. Cell Oncol (Dordr) 34: 307-313.
25. Mazumder S, Choudhary GS, Al-Harbi S, Almasan A (2012) Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Cancer Res 72: 3069-3079.
26. Harrison LR, Micha D, Brandenburg M, Simpson KL, Morrow CJ, et al. (2011) Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. J Clin Invest 121: 1075-1087.
27. Zhai D, Jin C, Satterthwait AC, Reed JC (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13: 1419-1421.
28. Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149.
29. Espona-Fiedler M, Soto-Cerrato V, Hosseini A, Lizcano JM, Guallar V, et al. (2012) Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. Biochem Pharmacol 83: 489-496.
30. Wei Y, Kadia T, Tong W, Zhang M, Jia Y, et al. (2010) The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res 16: 3923-3932.
31. Crawford N, Chacko AD, Savage KI, McCoy F, Redmond K, et al. (2011) Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apoptosis 16: 311-320.
32. Pan J, Cheng C, Verstovsek S, Chen Q, Jin Y, et al. (2010) The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett 293: 167-174.
33. Heidari N, Hicks MA, Harada H (2010) GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 1: e76.
34. McCoy F, Hurwitz J, McTavish N, Paul I, Barnes C, et al. (2010) Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis 1: e108.
35. Wanebo HJ, LeGolvan M, Paty PB, Saha S, Zuber M, et al. (2012) Meeting the biologic challenge of colorectal metastases. Clin Exp Metastasis 29: 821-839.
36. Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6: 449-458.
37. Yamaguchi H, Wyckoff J, Condeelis J (2005) Cell migration in tumors. Curr Opin Cell Biol 17: 559-564.
38. Schneider MR, Dahlhoff M, Horst D, Hirschi B, Trulzsch K, et al. (2010) A key role for E-cadherin in intestinal homeostasis and Paneth cell maturation. PLoS One 5: e14325.
39. Hermiston ML, Wong MH, Gordon JI (1996) Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev 10: 985-996.
40. Hazan RB, Qiao R, Keren R, Badano I, Suyama K (2004) Cadherin switch in tumor progression. Ann N Y Acad Sci 1014: 155-163.
41. Zinkel SS (2008) Investigation of the proapoptotic BCL-2 family member bid on the crossroad of the DNA damage response and apoptosis. Methods Enzymol 442: 231-250.
42. Janumyan YM, Sansam CG, Chattopadhyay A, Cheng N, Soucie EL, et al. (2003) Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J 22: 5459-5470.
43. Fujise K, Zhang D, Liu J, Yeh ET (2000) Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem 275: 39458-39465.
44. Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, et al. (2012) Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. J Hepatol 57: 995-1003.
45. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279.
46. Vick B, Weber A, Urbanik T, Maass T, Teufel A, et al. (2009) Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 49: 627-636.
47. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333.